Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALIA-1758 · 1 trial · 1 indication
Incidence, severity, seriousness, and causality of treatment-emergent adverse events (TEAEs)
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | Single Ascending Dose (SAD) cohorts |
| Placebo | PLACEBO_COMPARATOR | Single Ascending Dose (SAD) cohorts |
| Name | Type | Description |
|---|---|---|
| ALIA-1758 | DRUG | Intravenous or subcutaneous doses |
| Placebo | OTHER | Intravenous or subcutaneous doses |
Key Inclusion Criteria: * Participants must understand the nature of the trial and must provide signed and dated written informed consent in accordance with local regulations before the conduct of any trial-related procedures. * Healthy as determined by the Investigator, based on a medical evaluati...
Top 20 of 24 competitors
ALIA-1758 is an investigational small molecule being developed for the treatment of Alzheimer Disease. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied to assess its safety, tolerability, and pharmacokinetics in healthy participants.
ALIA-1758 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol ABBV. The company is conducting clinical trials to evaluate the drug's safety and pharmacokinetic profile in healthy volunteers.
ALIA-1758 is in Phase 1 clinical development. A Phase 1 trial has been completed, which evaluated the safety, tolerability, and pharmacokinetics of the drug in healthy participants. The drug remains investigational and is not yet approved for any use.
ALIA-1758 has one completed clinical trial registered as NCT06406348, titled "A Phase 1 Trial to Assess Safety, Tolerability and Pharmacokinetics of ALIA-1758 in Healthy Participants." The trial enrolled 53 participants in the United States and was a randomized, double-blind, placebo-controlled study.
ALIA-1758 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A Phase 1 trial has been completed to evaluate its safety and pharmacokinetics in healthy participants, but the drug has not yet received regulatory approval for the treatment of Alzheimer Disease.